# Systemic Sclerosis and Related Diseases **Type:** Topics **Canonical URL:** https://scholariq.org/topics/systemic-sclerosis-and-related-diseases/ ## Facts | Field | Value | | --- | --- | | Description | This cluster of papers focuses on the pathogenesis, clinical manifestations, and treatment of systemic sclerosis, with an emphasis on fibrosis, autoantibodies, pulmonary involvement, and the role of TGF-ß signaling. It also explores genetic markers, endothelial dysfunction, and various treatment approaches including immunosuppressive therapy for this complex autoimmune disease. | | Domain | Health Sciences | | Field | Medicine | | OpenAlex ID | t11330 | | Works | 350 | ## Topic papers all Showing 15 of 350. - [SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY INDEX](https://scholariq.org/papers/systemic-lupus-erythematosus-disease-activity-index/) - [Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis](https://scholariq.org/papers/rituximab-versus-cyclophosphamide-for-anca-associated-vasculitis/) - [Development of Autoantibodies before the Clinical Onset of Systemic Lupus Erythematosus](https://scholariq.org/papers/development-of-autoantibodies-before-the-clinical-onset-of-systemic-lupus/) - [The development and initial validation of the systemic lupus international collaborating clinics/American college of rheumatology damage index for systemic lupus erythematosus](https://scholariq.org/papers/the-development-and-initial-validation-of-the-systemic-lupus-international/) - [2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus](https://scholariq.org/papers/2019-european-league-against-rheumatism-american-college-of-rheumatology/) - [Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis](https://scholariq.org/papers/rituximab-versus-cyclophosphamide-in-anca-associated-renal-vasculitis/) - [Pathologic Classification of Diabetic Nephropathy](https://scholariq.org/papers/pathologic-classification-of-diabetic-nephropathy/) - [The classification of glomerulonephritis in systemic lupus erythematosus revisited](https://scholariq.org/papers/the-classification-of-glomerulonephritis-in-systemic-lupus-erythematosus-2/) - [2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus](https://scholariq.org/papers/2019-european-league-against-rheumatism-american-college-of-rheumatology-2/) - [The Management of Thrombosis in the Antiphospholipid-Antibody Syndrome](https://scholariq.org/papers/the-management-of-thrombosis-in-the-antiphospholipid-antibody-syndrome/) - [Prevalence and Correlates of Accelerated Atherosclerosis in Systemic Lupus Erythematosus](https://scholariq.org/papers/prevalence-and-correlates-of-accelerated-atherosclerosis-in-systemic-lupus/) - [Morbidity and Mortality in Systemic Lupus Erythematosus During a 10-Year Period](https://scholariq.org/papers/morbidity-and-mortality-in-systemic-lupus-erythematosus-during-a-10-year-period/) - [Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies](https://scholariq.org/papers/development-and-validation-of-a-consensus-methodology-for-the-classification-of/) - [Modification and validation of the Birmingham Vasculitis Activity Score (version 3)](https://scholariq.org/papers/modification-and-validation-of-the-birmingham-vasculitis-activity-score-version/) - [Platelet Activation in Unstable Coronary Disease](https://scholariq.org/papers/platelet-activation-in-unstable-coronary-disease/) ## Topic primary papers Showing 15 of 73. - [Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population](https://scholariq.org/papers/prevalence-incidence-survival-and-disease-characteristics-of-systemic-sclerosis/) - [Mapping and predicting mortality from systemic sclerosis](https://scholariq.org/papers/mapping-and-predicting-mortality-from-systemic-sclerosis/) - [Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma](https://scholariq.org/papers/myeloablative-autologous-stem-cell-transplantation-for-severe-scleroderma/) - [Effects of 1-Year Treatment with Cyclophosphamide on Outcomes at 2 Years in Scleroderma Lung Disease](https://scholariq.org/papers/effects-of-1-year-treatment-with-cyclophosphamide-on-outcomes-at-2-years-in/) - [Proteome-wide Analysis and CXCL4 as a Biomarker in Systemic Sclerosis](https://scholariq.org/papers/proteome-wide-analysis-and-cxcl4-as-a-biomarker-in-systemic-sclerosis/) - [Update on morphea](https://scholariq.org/papers/update-on-morphea/) - [Mortality and survival in systemic sclerosis: Systematic review and meta-analysis](https://scholariq.org/papers/mortality-and-survival-in-systemic-sclerosis-systematic-review-and-meta-analysis/) - [Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database](https://scholariq.org/papers/progressive-interstitial-lung-disease-in-patients-with-systemic-sclerosis/) - [Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients](https://scholariq.org/papers/fresolimumab-treatment-decreases-biomarkers-and-improves-clinical-symptoms-in/) - [Clinical aspects of autoimmune rheumatic diseases](https://scholariq.org/papers/clinical-aspects-of-autoimmune-rheumatic-diseases/) - [Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease](https://scholariq.org/papers/phase-i-ii-trial-of-autologous-stem-cell-transplantation-in-systemic-sclerosis/) - [European Dermatology Forum S1‐guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes](https://scholariq.org/papers/european-dermatology-forum-s1-guideline-on-the-diagnosis-and-treatment-of/) - [Distinct Autoimmune Syndromes in Morphea](https://scholariq.org/papers/distinct-autoimmune-syndromes-in-morphea/) - [Cutaneous Manifestations of Scleroderma and Scleroderma-Like Disorders: a Comprehensive Review](https://scholariq.org/papers/cutaneous-manifestations-of-scleroderma-and-scleroderma-like-disorders-a/) - [Fibronectin EDA Promotes Chronic Cutaneous Fibrosis Through Toll-Like Receptor Signaling](https://scholariq.org/papers/fibronectin-sup-eda-sup-promotes-chronic-cutaneous-fibrosis-through-toll-like/) --- Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.